Erudio Healtherudio.com
Sponsor
Merck KGaA (EMD Serono) trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Merck KGaA (EMD Serono) yet. Erudio has found public clinician commentary on 6 clinical trials sponsored by Merck KGaA (EMD Serono), including DeFi, INSIGHT 2, JAVELIN Solid Tumor and TrilynX. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (EMD Serono Research & Development Institute, Inc.; SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| INSIGHT 2 NCT03940703 · EMD Serono Research & Development Institute, Inc. DeepView → | MET-amplified EGFR-mutated advanced NSCLC with first-line osimertinib resistance | Phase 2 | Deep | View | |||
| DeFi NCT03785964 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany DeepView → | progressing desmoid tumors | Phase 3 | Deep | View | |||
| TrilynX NCT04459715 · EMD Serono Research & Development Institute, Inc. StandardView → | locally advanced head and neck squamous cell carcinoma | Phase 3 | Standard | View | |||
| JAVELIN Solid Tumor NCT01772004 · EMD Serono Research & Development Institute, Inc. StandardView → | metastatic or locally advanced solid tumors | Phase 1 | Standard | View | |||
| VISION NCT02864992 · EMD Serono Research & Development Institute, Inc. FocusedView → | Not given | Phase 2 | Focused | View | |||
| JAVELIN Bladder Medley NCT05327530 · EMD Serono Research & Development Institute, Inc. FocusedView → | first-line maintenance locally advanced or metastatic urothelial carcinoma | Phase 2 | Focused | View | |||